InvestorsHub Logo
Followers 0
Posts 152
Boards Moderated 0
Alias Born 06/06/2007

Re: None

Friday, 03/07/2008 2:11:54 PM

Friday, March 07, 2008 2:11:54 PM

Post# of 8473
Minyanville - Biotech Beat Down

Repros Therapeutics (RPRX) could be the poster child for the hedge fund failure issue I wrote about above. Its decline from the mid-teens was brought about by people surprised by a longer regulatory path for its two products. Forced selling from fund redemptions and scared individual investors did the rest. The reaction to a data presentation from Italy was a good example. The data had been discussed at length previously, but scared investors imagined something was wrong. This is true dev-stage biotech, with all the attendant risks of a company with no products on the market, but I like this one a great deal.

http://www.minyanville.com/articles/nstk-alny-dna-azn-jnj-amgn/index/a/16185/from/yahoo
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RPRX News